Depending on the type of alternative payment models, it could be more difficult or easier for practices to find overlaps and participate in multiple models, said Mike Fazio, senior vice president of client services, Archway Health.
Depending on the type of alternative payment models, it could be more difficult or easier for practices to find overlaps and participate in multiple models, said Mike Fazio, senior vice president of client services, Archway Health.
Transcript
As the country moves to value-based care, the number of alternative payment models is growing, and many practices are participating in more than one. Are they having trouble balancing multiple models?
It depends on the model. So, OCM [Oncology Care Model] involves so much of the patient mix of OCM practices and because of the care transformation components of the program from the get-go it’s been an area of focus for anyone that’s in OCM.
In some of the other programs, like BPCI [Bundled Payments for Care Improvement] Advanced, there is intersection and overlap with other programs, like the ACO [accountable care organization] program, for example. And those models, thought, BPCI is a great avenue to incent specialists within a primary care model, like an ACO. So, it does differ.
But from an OCM perspective we see that participants are very focused and with the movement toward downside risk in OCM, for those practices that make that choice this fall, definitely more focus on OCM because of that. Whereas a one-sided model, it’s a different beginning than being in a risk-based model.
Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs
June 10th 2025Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Without IRA Fix, COA Warns Community Oncology Practices Will Shut Down
June 30th 2025Ted Okon, MBA, of the Community Oncology Alliance discusses how community oncology faces a revenue crisis due to the Inflation Reduction Act's impact on Medicare reimbursement, risking patient access to vital cancer treatments.
Read More